GLP-1 weight loss claims on TikTok: what the data says

What did @futurethemonster actually say?

Nothing about GLP-1 medications. Not a single word. The transcript is a rap verse, almost certainly from Future's catalog, referencing mansions, jewelry, dancers, and stacked cash. Lyrics like "look at the diamond look at the wrist" and "look at them dollars and dollars a stack" are flex rap, full stop. There is no medical claim here, no health advice, and no mention of semaglutide, tirzepatide, weight loss, or anything adjacent to telehealth. This video was tagged under GLP-1 content, but the content itself contains zero relevant health information.

Does the science back this up?

There is no scientific claim to evaluate. The video makes no assertions about physiology, pharmacology, or metabolic health. Since we cannot fact-check a lyric about wrist diamonds against a clinical trial, we will use this space to cover what GLP-1 science actually looks like in 2024, so you have a baseline when content in this category does make real claims.

GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced mean weight reductions of up to 22.5% in adults with obesity. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg achieved roughly 14.9% average body weight reduction versus placebo. These are not trivial numbers. They represent the most significant pharmacological weight loss data published in decades.

What did they get wrong (or right)?

The creator got nothing wrong about GLP-1 drugs because they said nothing about GLP-1 drugs. That is not a compliment. It means this video was miscategorized, mislabeled, or incorrectly surfaced under health content. That is a platform-level problem, not a creator problem.

What is worth flagging: when rap or celebrity content gets pulled into health content categories algorithmically, viewers who are genuinely researching weight loss medications may encounter it and draw their own connections. The association between wealth signaling and body transformation narratives is real in popular culture. A viewer primed to research GLP-1s who lands on aspirational flex content could, in some contexts, reinforce a mindset that these medications are a luxury product rather than a medical intervention. That framing has consequences. It is not this creator's fault, but it is worth naming.

What should you actually know?

If you landed here looking for real information about GLP-1 medications, here is the short version. Semaglutide and tirzepatide are FDA-approved medications prescribed by licensed clinicians. They are not lifestyle supplements. They are not interchangeable with each other or with compounded versions. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) confirmed that semaglutide 2.4mg reduced major cardiovascular events by 20% in adults with obesity and established cardiovascular disease, independent of weight loss. That is a meaningful finding that extends the clinical rationale beyond aesthetics.

Common side effects include nausea, vomiting, constipation, and in some cases more serious outcomes like pancreatitis or gastroparesis, though rates of severe adverse events in trials were low. Anyone considering these medications should do so under medical supervision, with regular follow-up, and with realistic expectations about what the drugs do and do not do long-term.